Long Non-Coding RNAs in Ovarian Cancer: Mechanistic Insights and Clinical Applications
Cancers · 30.01.2025 · 17 (3) · 472
DOI: 10.3390/cancers17030472 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 30.01.2025. Verfasst von Sneha Basu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Stephenson Cancer Center, The University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 251 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Department of Defence, NIGMS NIH HHS, NCI NIH HHS.
Abstract (Originalsprache)
Background/Objectives: Ovarian cancer is a leading cause of gynecological cancer mortality worldwide, often diagnosed at advanced stages due to vague symptoms and the lack of effective early detection methods. Long non-coding RNAs (lncRNAs) have emerged as key regulators in cancer biology, influencing cellular processes such as proliferation, apoptosis, and chemoresistance. This review explores the multifaceted roles of lncRNAs in ovarian cancer pathogenesis and their potential as biomarkers and therapeutic targets.
Methods
A comprehensive literature review was conducted to analyze the structural and functional characteristics of lncRNAs and their contributions to ovarian cancer biology. This includes their regulatory mechanisms, interactions with signaling pathways, and implications for therapeutic resistance. Advanced bioinformatics and omics approaches were also evaluated for their potential in lncRNA research.
Results
The review highlights the dual role of lncRNAs as oncogenes and tumor suppressors, modulating processes such as cell proliferation, invasion, and angiogenesis. Specific lncRNAs, such as HOTAIR and GAS5, demonstrate significant potential as diagnostic biomarkers and therapeutic targets. Emerging technologies, such as single-cell sequencing, provide valuable insights into the tumor microenvironment and the heterogeneity of lncRNA expression.
Conclusions
LncRNAs hold transformative potential in advancing ovarian cancer diagnosis, prognosis, and treatment. Targeting lncRNAs or their associated pathways offers promising strategies to overcome therapy resistance and enhance personalized medicine. Continued research integrating omics and bioinformatics will be essential to unlock the full clinical potential of lncRNAs in ovarian cancer management.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Stephenson Cancer Center, The University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.
- Department of Pathology, The University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.
- Department of Cell Biology, The University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.
ORCID-Profile: Revathy Nadhan, Danny N Dhanasekaran
Förderung
- Department of Defence
- NIGMS NIH HHS
- NCI NIH HHS
- NIH HHS
- Department of Defense Ovarian Cancer Research Program Award
- National Institute of General Medical Sciences National Institute of General Medical Sciences
- National Cancer Institute of the National Institutes of Health
Zitieren
APA
Basu, S., Nadhan, R., & Dhanasekaran, D. N. (2025). Long Non-Coding RNAs in Ovarian Cancer: Mechanistic Insights and Clinical Applications. Cancers, 17(3), 472. https://doi.org/10.3390/cancers17030472
Vancouver
Basu S, Nadhan R, Dhanasekaran DN. Long Non-Coding RNAs in Ovarian Cancer: Mechanistic Insights and Clinical Applications. Cancers. 2025;17(3):472. doi:10.3390/cancers17030472
BibTeX
@article{Basu2025,
author = {Basu, Sneha and Nadhan, Revathy and Dhanasekaran, Danny N},
title = {Long Non-Coding RNAs in Ovarian Cancer: Mechanistic Insights and Clinical Applications},
journal = {Cancers},
year = {2025},
volume = {17},
number = {3},
pages = {472},
doi = {10.3390/cancers17030472}
}
EUVIMED